Hypocalcemia induced by tyrosine kinase inhibitors: targeted treatment with 'untargeted' side effects

Acta Oncol. 2020 Jun;59(6):726-729. doi: 10.1080/0284186X.2020.1726455. Epub 2020 Feb 14.

Authors

Annika M A Berends¹, Anouk N A van der Horst-Schrivers¹, Sjoukje F Oosting², Ellen W Kapiteijn³, Jan Willem B de Groot⁴, Thera P Links¹

Affiliations

¹ Department of Endocrinology, Division of Internal Medicine, University Medical Center Groningen, Groningen, The Netherlands.
² Department of Medical Oncology, Division of Internal Medicine, University Medical Center Groningen, Groningen, The Netherlands.
³ Department of Medical Oncology, Division of Internal Medicine, Leiden University Medical Center, Leiden, The Netherlands.
⁴ Isala Oncology Center, Zwolle, The Netherlands.

PMID: 32056474
DOI: 10.1080/0284186X.2020.1726455

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adenocarcinoma, Follicular / blood
Adenocarcinoma, Follicular / drug therapy*
Adenocarcinoma, Follicular / enzymology
Adenocarcinoma, Follicular / pathology
Aged
Calcium / blood*
Female
Humans
Hypocalcemia / blood
Hypocalcemia / chemically induced*
Hypocalcemia / enzymology
Hypocalcemia / pathology
Phenylurea Compounds / administration & dosage
Phenylurea Compounds / adverse effects*
Protein Kinase Inhibitors / administration & dosage
Protein Kinase Inhibitors / adverse effects*
Quinolines / administration & dosage
Quinolines / adverse effects*
Thyroid Neoplasms / blood
Thyroid Neoplasms / drug therapy*
Thyroid Neoplasms / pathology

Substances

Phenylurea Compounds
Protein Kinase Inhibitors
Quinolines
lenvatinib
Calcium